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Abstracts A51
there are established agencies that evaluate new pharmaceuticals to inform health care 
policy decisions (e.g., the HAS in France and NICE in the UK). This analysis will 
consider the strengths and weaknesses of European health technology bodies (HTA) 
and provide insight for the implementation of CER and how lessons learned from the 
UK and France might help improve efﬁciency and outcomes in oncology in the US. 
METHODS: Secondary research will be used to review how HTA bodies evaluate 
oncologics and assess their impact on market access. These countries were selected as 
they represent the extremes of HTA assessment in Europe. Findings from this research 
will then be contrasted against current market access in the US. RESULTS: While 
France evaluates new products on innovation and clinical value the UK largely bases 
market access decisions on cost-effectiveness. Consequently, many new oncology 
agents available in France have been denied funding in the UK. Meanwhile, insured 
Americans have relatively open access. CONCLUSIONS: Cancer remains the second 
leading cause of death in the US and is a growing health care burden. Therefore better 
informed policy decisions on the efﬁcient use of clinical services for oncology are 
critical. This analysis suggests that there is potential for the US to optimize on the 
European experiences when considering the adoption of a CER tool for oncology 
drugs management. Speciﬁcally, if the US does adopt a formal CER entity, it may wish 
to avoid using NICE-like economic-based outcomes to change clinical practice, but 
and aim to play an advisory role to facilitate better informed strategic decisions 
(HAS-like).
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OBJECTIVES: In Canada, the interim Joint Oncology Drug Review (JODR) conducts 
health technology assessments for all oncology products and provides funding recom-
mendations to participating provinces. Summaries of these recommendations are 
publically available, however investigation of the potential factors that inﬂuence 
these decisions has not been conducted. Furthermore, the acceptable incremental 
cost-effectiveness ratio (ICER) used by the JODR has not been published. This 
analysis was conducted to assess the differences in the average ICER between the 
JODR’s positive and negative recommendations and determine the relative inﬂuence 
of cost-effectiveness evidence on decision-making. METHODS: A literature search 
for pharmacoeconomic data was conducted for all 24 drugs with cancer indications 
reviewed by the JODR and made publicly available between March 2007 and Decem-
ber 2009. Cost-effectiveness data was extracted and converted into Canadian cur-
rency (CAD) to provide an estimate for Canadian public payers. The JODR and 
Ontario Public Drug Plan (OPDP) recommendations and decisions were analyzed in 
the context of these ICER values. RESULTS: Cost-effectiveness literature was found 
for 18 of the 24 drugs and of those, only 15 had published ICER values. ICER 
values ranged from approximately CAD$10,000/QALY to CAD$127,000/QALY. 
The average ICER of those cancer drugs considered to be cost-effective by the JODR 
was CAD$44,269/QALY, whereas the ICER for drugs considered not cost-effective 
was CAD$75,882/QALY (p = 0.10). Furthermore, drugs that were recommended 
for funding had a lower ICER when compared to those that were not recommended 
for funding ($57,578 vs. $81,490/QALY, p = 0.50). CONCLUSIONS: These ﬁndings 
suggest that while the ICER may be an important factor in the JODR decision-
making process, a careful examination of all factors leading to ﬁnal reimbursement 
decisions is needed to fully understand the relative importance of the ICER. Further 
research is required to determine if there are differences in the application of the 
ICER in decision-making processes for oncology medications versus other disease 
areas.
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BACKGROUND: Breast cancer is the most common type of cancer among women 
world wide ranking second in mortality from cancer. Bse is a screaning method that 
should be taught at an early age so as to educate women about the importance of 
early detection of breast cancer. OBJECTIVES: The aim of this study was to evaluate 
the level of knowledge of midwifery and nursing student regarding breast self –exami-
nation . METHODS: This study is descriptive on 23 midwifery and 69 nursing 
student.data collection tool was a questionnaire the included6 questions about demo-
graphic characteristics, and 14 question about knowledge breast self examination. 
Data analyzed by descriptive statistics. RESULTS: Our results show that the average 
age being (21–35),majo rity of them are single (%67/4)and (%29/3) twin. Our result 
showed no signiﬁcant differences in midwifery and nursing knowledge.(p > 5%). Our 
result showed the students of midwifery and nursing have mild knowledge. CONCLU-
SIONS: It seems that despite of the importance of the BSE in early diagnosis of breast 
cancer the majority of women have poor knowledge and practice about BSE.Based on 
the positive attitude of most women about BSE, it is that increasing the knowledge of 
women by education ways of breast cancer, especially BSE, this will be available by 
more attention of public health centers, TV and newspaper for increasing women 
awareness. Key word:breast,student,cancer,self examination.
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OBJECTIVES: Expert groups recommend men with local stage prostate cancer seek 
second opinions before choosing a management option. The nature of the physician-
patient interaction and outcomes for second versus primary opinion visits are 
unknown. METHODS: Newly diagnosed local stage prostate cancer patients and 
physicians at urology practices in three states participated in a survey of patient and 
doctor decision making following biopsy but prior to initiating treatment. Physicians 
were asked about the clinical status of the patient’s cancer, treatments discussed and 
recommended, and what factors most inﬂuenced the physician’s treatment 
recommendation(s). Patients were asked their treatment preference and what treat-
ments the physician recommended. RESULTS: A total of 238 local stage prostate 
cancer patients and their urologists completed surveys. Patient characteristics were: 
47% aged 60–69; 71% white, 16% black, 11% Hispanic; 49% had an income of 
≥$75,000. Ninety-ﬁve men were presenting for a primary consultation; 143 men were 
presenting for a second opinion. Among the initial consultation group, 64% were 
considering/planning a prostatectomy. Among the group seeking a second opinion, 
83% were considering/planning a prostatectomy. Of those seeking a primary recom-
mendation 59% had low risk disease, similar to the second opinion setting (54%). 
For low risk patients (primary vs. secondary opinions, respectively), physicians recom-
mended surgery for 80%/90%, external radiation for 38%/16%, seeds for 52%/14%, 
and watchful waiting for 25%/16%. In multivariate analysis, during an initial con-
sultation physicians recommended 0.51 more treatments (standard error 0.12, p < 
0.001) and were half as likely to consider the patient’s preference as a factor in their 
recommendations (OR 0.49, CI 026–0.95). CONCLUSIONS: Patient preferences and 
physician recommendations differ substantially in secondary versus primary opinion 
settings. In secondary opinion visits, patients are more likely to want prostatectomy 
and physicians are more likely to consider patient preference when making recom-
mendations. This is true even for men with low risk disease.
PCN146
REAL WORLD DATA ON MULTIPLE MYELOMA (MM) TREATMENT IN 
BRAZIL: GUIDANCE FOR THE PRIVATE HEALTH CARE SYSTEM (PHS)
Alves AFF, Castro APC, Clark LGO, Santos FS, Clark O, Engel T, Pegoretti B
Evidencias, Campinas, Brazil
OBJECTIVES: New treatments in oncology frequently imply in higher costs. Histori-
cally there is a lack of statistical data on cancer treatments in PHS in Brazil. Higher 
costs combined to lack of information may result in waste of resources. We present 
here real world data (RWD) on MM treatment collected from a dedicated database 
of cancer treatments Evidencias® (www.evidencias.com.br). METHODS: Between 
November of 2007 and October 2009 we retrieved all patients with MM registered 
on Evidencias®. Anthropometric data, staging, types of treatment, duration, and cost 
of chemotherapy and adjunctive therapies (AT) such as antiemetics, erythropoietin, 
colony stimulating factors and bisphosphonates were extracted. RESULTS: We identi-
ﬁed 98 patients (53% women and 47% men). The mean body surface area (BSA) 
was1.73 m2. Staging was stratiﬁed as follows: 21% Stage I, 8% stage II and 54% 
stage III. In 17% of the cases stage information was unavailable. Total cost of drugs 
was US$1,709,404.50. Chemotherapy drugs represented US$1,214,275.03 (71%) of 
which 98% (US$1,192,849.98) were due to the use of Bortezomib and 29% 
(US$495,129.46) to AT. Bortezomib was present in 57% of the treatments either 
isolated (42%) or combined to other chemotherapy (15%). Cyclophosphamide was 
used in 20% of the treatments, Doxorubicin in 18% and Melphalan in 5%. Mean 
duration of treatment was 3.9 cycles of chemotherapy. CONCLUSIONS: Real world 
data although a fundamental tool to guide health care providers in the correct alloca-
tion of resources, is still rare in Brazil e Latin America. Bortezomib is used in 57% of 
MM treatments but represents 98% of chemotherapy costs.
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OBJECTIVES: This study evaluated characteristics of postmenopausal women (PMW) 
who initiated raloxifene (RLX) therapy before and after the approval of the invasive 
breast cancer (BC) risk reduction (IBCRR) indications. METHODS: PMW 50 years 
and older with at least one claim for RLX in 2005–2008 and continuous enrollment 
over the study period (Jan 2004-Dec 2008) were identiﬁed in a large national com-
mercial and Medicare supplemental claims database. PMW on RLX were evaluated 
based on clinical and demographic variables such as age, provider specialty, fractures, 
bone mineral density (BMD) screening, Chronic Disease Score (CDS), family history 
of BC, and mammograms 12 months before and 12 months after the IBCRR indication 
